Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology

[1]  M. Oshimura,et al.  Gender Difference of Hepatic and Intestinal CYP3A4 in CYP3AHumanized Mice Generated by a Human Chromosome-engineering Technique. , 2017, Drug Metabolism Letters.

[2]  T. Gaj,et al.  Genome-Editing Technologies: Principles and Applications. , 2016, Cold Spring Harbor perspectives in biology.

[3]  M. Ikawa,et al.  CRISPR/Cas9 mediated genome editing in ES cells and its application for chimeric analysis in mice , 2016, Scientific Reports.

[4]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[5]  Ying Guo,et al.  Genetic variation of CYP3A5 influences paclitaxel/carboplatin‐induced toxicity in Chinese epithelial ovarian cancer patients , 2016, Journal of clinical pharmacology.

[6]  D. Satoh,et al.  Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model , 2016, Scientific Reports.

[7]  R. Eils,et al.  CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma , 2016, Nature Medicine.

[8]  D. Hu,et al.  Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk , 2016, Drug metabolism reviews.

[9]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[10]  H. Lerche,et al.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature , 2015, Clinical Pharmacokinetics.

[11]  M. Oshimura,et al.  A novel and stable mouse artificial chromosome vector. , 2014, ACS synthetic biology.

[12]  Su-Jun Lee,et al.  Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy , 2014, Drug metabolism and drug interactions.

[13]  I. Cascorbi,et al.  Functional Gene Variants of CYP3A4 , 2014, Clinical pharmacology and therapeutics.

[14]  R. Obach,et al.  Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide) , 2014, Drug Metabolism and Disposition.

[15]  M. Oshimura,et al.  Highly stable maintenance of a mouse artificial chromosome in human cells and mice. , 2013, Biochemical and biophysical research communications.

[16]  Yoshitaka Fujihara,et al.  Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA , 2013, Scientific Reports.

[17]  Tetsushi Sakuma,et al.  Efficient TALEN construction and evaluation methods for human cell and animal applications , 2013, Genes to cells : devoted to molecular & cellular mechanisms.

[18]  M. Oshimura,et al.  Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. , 2013, Human molecular genetics.

[19]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[20]  I. Macphee.  Pharmacogenetic biomarkers: cytochrome P450 3A5. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[21]  Russ B Altman,et al.  PharmGKB summary: very important pharmacogene information for CYP3A5. , 2012, Pharmacogenetics and genomics.

[22]  M. McArthur,et al.  Mouse models for the p53 R72P polymorphism mimic human phenotypes. , 2010, Cancer research.

[23]  J. Beijnen,et al.  Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam , 2009, Drug Metabolism and Disposition.

[24]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[25]  T. Cresteil,et al.  CYP3A5 mRNA Degradation by Nonsense-Mediated mRNA Decay , 2005, Molecular Pharmacology.

[26]  Ronald N. Hines,et al.  Developmental Expression of the Major Human Hepatic CYP3A Enzymes , 2003, Journal of Pharmacology and Experimental Therapeutics.

[27]  D. Greenblatt,et al.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[28]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  J. Azuma,et al.  Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.

[30]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[31]  D. Greenblatt,et al.  Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. , 2000, The Journal of pharmacology and experimental therapeutics.

[32]  T Ishizaki,et al.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.

[33]  Frederick E. Petry,et al.  Principles and Applications , 1997 .

[34]  T. Cresteil,et al.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.

[35]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[36]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[37]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.